BioSpace News Archive

The new Agritek Holdings and acquisition of the Apex distribution licensed division will allow the Company to join forces to launch the “Higher Society” premium cannabis brand initially in California in order to drive revenue for both companies.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Beacon Discovery today announced that they entered into a strategic multi-year partnership (Project Cabrillo) aimed at building novel medicines across a range of G protein-coupled receptor (GPCR) targets.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain institutional investors for the sale of an aggregate of 2,418,322 series A units (“Series A Units”) and series B units (“Series B Units” and together with the Series A Units, the “Units”) at a price of US$4.1351 per Series A Unit and US$4.135 per Series B Unit

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the New England Journal of Medicine (NEJM) published an independently peer-reviewed article on up to three years of data from an ongoing Phase 1/2 study to evaluate safety and efficacy of investigational AAV gene therapy, valoctocogene roxaparvovec, for severe hemophilia A.

Innate Pharma SA announced that the European Medicines Agency has accepted the Marketing Authorization Application for Lumoxiti®, a first-in-class medicine indicated for adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

Mesoblast Limited, global leader in cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration has confirmed receipt of Mesoblast’s filing of clinical efficacy and safety data for remestemcel-L in its rolling Biologics License Application for the treatment of children with steroid-refractory acute graft versus host disease.

The warrants will have a five year-term and an exercise price of US$2.45 per share.

The company will provide an overview of the business and discuss recent corporate achievements that position it to further extend its leadership in the market.

Liam Kelly, President and CEO, Teleflex Incorporated (NYSE:TFX), is scheduled to speak at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, California

Under the terms of the agreement, Amedisys acquired 100 percent of its membership interests.